These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 28903983

  • 1. Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.
    Das D, Savarese G, Dahlström U, Fu M, Howlett J, Ezekowitz JA, Lund LH.
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28903983
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L, Ford I, SHIFT Investigators.
    J Am Coll Cardiol; 2012 May 29; 59(22):1938-45. PubMed ID: 22617188
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
    Böhm M, Robertson M, Ford I, Borer JS, Komajda M, Kindermann I, Maack C, Lainscak M, Swedberg K, Tavazzi L.
    Am J Cardiol; 2015 Dec 15; 116(12):1890-7. PubMed ID: 26508709
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
    Borer JS, Böhm M, Ford I, Robertson M, Komajda M, Tavazzi L, Swedberg K, SHIFT Investigators.
    Am J Cardiol; 2014 Feb 01; 113(3):497-503. PubMed ID: 24332674
    [Abstract] [Full Text] [Related]

  • 8. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
    Hu DY, Huang DJ, Yuan ZY, Zhao RP, Yan XW, Wang MH, Chinese Investigators of SHIFT Study.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar 24; 45(3):190-197. PubMed ID: 28316174
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Early NT-proBNP decrease with ivabradine in ambulatory patients with systolic heart failure.
    Sargento L, Satendra M, Longo S, Lousada N, Palma dos Reis R.
    Clin Cardiol; 2013 Nov 24; 36(11):677-82. PubMed ID: 23929789
    [Abstract] [Full Text] [Related]

  • 11. Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris.
    Borer JS, Swedberg K, Komajda M, Ford I, Tavazzi L, Böhm M, Depre C, Wu Y, Maya J, Dominjon F.
    Cardiology; 2017 Nov 24; 136(2):138-144. PubMed ID: 27614723
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM.
    Am J Cardiovasc Drugs; 2012 Dec 01; 12(6):415-26. PubMed ID: 23181944
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study.
    Bagriy AE, Schukina EV, Samoilova OV, Pricolota OA, Malovichko SI, Pricolota AV, Bagriy EA.
    Adv Ther; 2015 Feb 01; 32(2):108-19. PubMed ID: 25700807
    [Abstract] [Full Text] [Related]

  • 16. Prescribing patterns to optimize heart rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period.
    Dierckx R, Cleland JG, Parsons S, Putzu P, Pellicori P, Dicken B, Boyalla V, Clark AL.
    JACC Heart Fail; 2015 Mar 01; 3(3):224-30. PubMed ID: 25650369
    [Abstract] [Full Text] [Related]

  • 17. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure.
    Bonnet D, Berger F, Jokinen E, Kantor PF, Daubeney PEF.
    J Am Coll Cardiol; 2017 Sep 05; 70(10):1262-1272. PubMed ID: 28859790
    [Abstract] [Full Text] [Related]

  • 18. Advances in the management of heart failure: the role of ivabradine.
    Müller-Werdan U, Stöckl G, Werdan K.
    Vasc Health Risk Manag; 2016 Sep 05; 12():453-470. PubMed ID: 27895488
    [Abstract] [Full Text] [Related]

  • 19. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
    Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators.
    Lancet; 2010 Sep 11; 376(9744):875-85. PubMed ID: 20801500
    [Abstract] [Full Text] [Related]

  • 20. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice.
    Di Franco A, Sarullo FM, Salerno Y, Figliozzi S, Parrinello R, Di Pasquale P, Lanza GA.
    Am J Cardiovasc Drugs; 2014 Apr 11; 14(2):101-10. PubMed ID: 24327100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.